Interactive Resource
Frontotemporal Dementia Research Pipeline
This tracker focuses on treatments being studied to change the underlying biology or course of frontotemporal dementia (FTD), rather than medications being studied only to manage symptoms.
FTD is not one single disease. Some experimental treatments are designed only for people with a particular genetic or biological form of FTD. Where relevant, each treatment is associated with the biological or genetic subtype it targets.
Select a treatment to see how it works, what the evidence shows so far, and where to find its registered clinical trial.
Treatment Pathways
Managing Symptoms Now
Treatments and strategies currently used to help with symptoms and day-to-day function.
Explore symptom managementTreatments Being Studied
Investigational approaches researchers are testing to slow, prevent, or change the underlying disease.
Currently viewingWhy does this pipeline contain so many treatments for inherited FTD?
FTD is not one disease. Some forms are caused by inherited changes in genes such as GRN, C9orf72, and MAPT.
Knowing the specific genetic cause gives researchers a clearer biological target, which is why many experimental treatments currently focus on inherited forms of FTD.
People with sporadic FTD or other genetic forms currently have fewer disease-targeted treatments in clinical trials.
What do the phases mean?
Phase 1
Safety & dosingDoes it appear safe enough to keep studying?
The first studies in people. Researchers are primarily looking at safety, dosing, and how the treatment behaves in the body.
Phase 2
Early signalsDoes it affect its target, and is there evidence it might help?
The treatment is tested in more people. Researchers continue studying safety while looking for evidence that it affects its intended target and may provide clinical benefit.
Phase 3
Large-scale testingDoes it meaningfully help patients, and is it sufficiently safe?
Large studies designed to determine whether the treatment is effective and sufficiently safe in the intended patient population. Positive Phase 3 results can support an application for regulatory approval.
A later phase does not mean a treatment is proven to work. Until a treatment has successfully completed clinical testing and received regulatory approval, it remains investigational.
This is a curated educational resource, not a comprehensive registry. Treatments are selected to illustrate clinically relevant approaches being studied for each disease. Trial status, enrollment, and eligibility should always be confirmed directly through ClinicalTrials.gov.
This pipeline is under active review. Treatment details and trial information are being expanded as individual programs are verified.